Panoptica Inc. is a private clinical stage biopharmaceutical company based in Bernardsville, NJ, dedicated to developing innovative treatments for sight-threatening eye diseases caused by abnormal blood vessels. Their focus is on creating a topical eye drop alternative to intravitreal injections for conditions such as neovascular age-related macular degeneration (wet AMD) and diabetic retinopathy.
Backed by reputable venture companies like Third Rock Ventures and SV Health Investors, Panoptica's investigational eye drop, Pan 90806, shows promise in revolutionizing the treatment of neovascular eye diseases by potentially reducing injection burden and improving patient comfort, safety, and adherence. Their commitment to helping patients achieve optimal vision outcomes drives their efforts to develop new ocular therapies for a better quality of life.
Generated from the website